[{"indications": "Indications\u00a0\n(From Trastuzumab: British National Formulary)\nTrastuzumab and product literature", "name": "TRASTUZUMAB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.5 Other antineoplastic drugs", "Trastuzumab"], "cautions": "Cautions\u00a0see section 8.1 and notes above; symptomatic heart\r\nfailure, history of hypertension, coronary artery disease, uncontrolled arrhythmiasCardiotoxicity\u00a0Monitor cardiac function\r\nbefore and during treatment\u2014for details of monitoring\r\nand managing cardiotoxicity, consult product literature", "side-effects": "Side-effects\u00a0see section 8.1; also\r\ninfusion-related side-effects (possibly delayed onset), including\r\nchills, fever, hypersensitivity reactions such as anaphylaxis, urticaria,\r\nand angioedema; gastro-intestinal symptoms, hepatitis; cardiotoxicity\r\n(see also above), chest pain, hypertension, hypotension; pulmonary\r\nevents (possibly delayed onset); headache, taste disturbance, anxiety,\r\nmalaise, depression, insomnia, drowsiness, dizziness, paraesthesia,\r\ntremor, asthenia, peripheral neuropathy, hypertonia, paresis; mastitis,\r\nurinary-tract infection; ecchymosis, oedema, weight loss; arthralgia,\r\nmyalgia, arthritis, bone pain, leg cramps; dry eye, increased lacrimation;\r\nrash, pruritus, sweating, dry skin, alopecia, acne, nail disorders", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/88513.htm", "doses": ["See Doses"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid\u2014oligohydramnios reported;\r\neffective contraception must be used during treatment and for 6 months\r\nafter stopping"}]